Evidence map›Paper›PMID 34745967›Full record

ArticleFrontiers in oncology2021

Improving Quality Indicator of Melanoma Management - Change of Melanoma Mortality-to-Incidence Rate Ratio Based on a Hungarian Nationwide Retrospective Study.

Máté Várnai, Zoltán Kiss, Rolland Gyulai, Judit Oláh, Péter Holló, Gabriella Emri, András Csejtei, István Kenessey, Angéla Benedek, Zoltán Polányi and 10 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Máté VárnaiCenter for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
Zoltán KissMSD Pharma Hungary Ltd., Budapest, Hungary.
Rolland GyulaiDepartment of Dermatology, Venerology and Oncodermatology, Medical School and Clinical Center, University of Pécs, Pécs, Hungary.
Judit OláhDepartment of Oncotherapy, University of Szeged, Szeged, Hungary.
Péter HollóDepartment of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
Gabriella EmriDepartment of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
András CsejteiDepartment of Oncoradiology, Markusovszky University Teaching Hospital, Szombathely, Hungary.
István KenesseyNational Institute of Oncology, Budapest, Hungary.
Angéla BenedekMSD Pharma Hungary Ltd., Budapest, Hungary.
Zoltán PolányiMSD Pharma Hungary Ltd., Budapest, Hungary.
Zsófia Nagy-ErdeiMSD Pharma Hungary Ltd., Budapest, Hungary.
Andrea DánielMSD Pharma Hungary Ltd., Budapest, Hungary.
Kata KnollmajerMSD Pharma Hungary Ltd., Budapest, Hungary.
György RokszinRxTarget Ltd., Szolnok, Hungary.
Ibolya FábiánRxTarget Ltd., Szolnok, Hungary.
Zsófia BarczaSyntesia Medical Communications Ltd., Budapest, Hungary.
Csaba PolgárNational Institute of Oncology, Budapest, Hungary.
Balázs NagyCenter for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
Gabriella LiszkayNational Institute of Oncology, Budapest, Hungary.
Zoltán VokóCenter for Health Technology Assessment, Semmelweis University, Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe incidence of melanoma has been increasing in the last decades. A retrospective Hungarian epidemiological study provided real-world data on incidence and mortality rates. There have been changing trends in incidence in Hungary in the last decade and mortality decreased, shifting mortality-to-incidence rate ratios (MIR). MIR is an indicator of cancer management quality.

objectivesOur aim is to show the changes of melanoma MIR in Hungary between 2011 and 2018 and to compare the real-world evidence-based results of our Hungarian nationwide retrospective study with other European countries.

methodsMIR is calculated from the age-specific standardized incidence and mortality rates from our study. Annual MIR values are presented for the total population and for both sexes between 2011 and 2018, along with 95% confidence intervals. Comparison with European countries are shown for 2012 and 2018 based on the GLOBOCAN database and Eurostat health care expenditure per capita data.

resultsMIR decreased by 0.035 during the study years. The decrease was same in both sexes (0.031). Male had higher MIRs in all study years. In both 2012 and 2018, Hungarian MIR in both sexes was lower than the European Union average (males: 0.192 vs. 0.212 and 0.148 vs. 0.174 respectively, women: 0.107 vs. 0.129 and 0.083 vs. 0.107 respectively). DISCUSSION: Hungarian mortality-to-incidence ratio is the lowest in Central and Eastern Europe and is close to the level of Western and Northern European countries. The results are driven by the high number of new diagnosed melanoma cases.

Indexed as

Hungaryincidence ratemelanomamortality ratemortality-to-incidence ratio

Identifiers

PMID34745967
PMCPMC8570304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.